A graphene-based field-effect transistor sensor paired with a molecularly imprinted polymer membrane for highly sensitive, selective, and low-cost detection of acrylamide. The technology leverages graphene's sensitivity to charged molecules and a selective polymer membrane to enable rapid, accurate acrylamide detection with a target detection limit below 0.1 ppb.
This solution is a chemical sensor built on a graphene field-effect transistor (FET) combined with a molecularly imprinted polymer (MIP) membrane for the ultra-sensitive detection of acrylamide. Acrylamide is a known carcinogen commonly found in heated starchy foods, coffee, and certain industrial processes, making reliable detection important for food safety, public health, and industrial quality control.
The core value proposition is a sensor that delivers high sensitivity, selectivity, and accuracy while remaining low-cost and suitable for mass production. By pairing graphene's unique electrical properties with a polymer membrane engineered to selectively bind acrylamide, the sensor can identify trace amounts of acrylamide in complex sample matrices. Potential applications include food safety testing, water quality monitoring, industrial process control, and environmental surveillance.
How it works:
Key features and demonstrated capabilities:
Target performance for acrylamide detection:
The underlying graphene FET sensor platform has been validated through prior work on phosphate and cancer biomarker detection, demonstrating detection limits as low as 0.1 ppt and rapid response times. The acrylamide-specific sensor is at an earlier development stage. Future validation involves synthesizing acrylamide-selective molecularly imprinted polymers with optimized formulations, coating them onto graphene transistors, and evaluating sensitivity and detection limits. Estimated development time is approximately one year. The team is seeking partnership support for field testing and funding for key personnel.
The University of Minnesota is a flagship, comprehensive public research university spanning multiple campuses, with a large research enterprise and clinical integration. Industry engages through co-located labs on the Twin Cities campuses, access to an academic health system for clinical translation, and pilot and field-testing facilities that speed scale-up. A statewide extension network and outreach centers provide real-world sites and data partnerships across Minnesota, while proximity to a dense medtech and Fortune 500 corridor enables frequent collaboration. Research is supported by competitive federal funding, including NIH, NSF, DOE, USDA, and DoD. A dedicated technology transfer office manages IP, licensing, sponsored research agreements, and startup incubation to speed commercialization.